TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02495350

Intervention type: OTHER
Intervention: Questionarie
Description: Parturients will be asked to fill out a labor satisfaction questionnaire detailing initial desire for epidural analgesia, final desire for epidural analgesia, adequacy of pain relief during labor and satisfaction with laborOn the third day postoperatively the parturients will be called and assessed for mood and signs of postpartum depression using Edinborough Postnatal Depression scale validated into Hebrew (10) , and we will assess whether or not they are breastfeeding.~At 6 weeks we will follow-up to assess breastfeeding duration ,and postpartum depression using the Edinborough Postnatal Depression scale.~Our comparison will include average pain scores, breast feeding success, and postpartum depression assessment.

Intervention type: OTHER
Intervention: Questionarie
Description: Parturients will be asked to fill out a labor satisfaction questionnaire detailing initial desire for epidural analgesia, final desire for epidural analgesia, adequacy of pain relief during labor and satisfaction with laborOn the third day postoperatively the parturients will be called and assessed for mood and signs of postpartum depression using Edinborough Postnatal Depression scale validated into Hebrew (10) , and we will assess whether or not they are breastfeeding.~At 6 weeks we will follow-up to assess breastfeeding duration ,and postpartum depression using the Edinborough Postnatal Depression scale.~Our comparison will include average pain scores, breast feeding success, and postpartum depression assessment.
Study: NCT00932425

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardionet Mobile Cardiac Outpatient Telemetry (MCOT)
Description: Patients will be assigned to wear the telemetry device for 21 days
Study: NCT02320955

Intervention type: PROCEDURE
Intervention: Reimplantation of cryoconserved bone flap
Description: A bone flap, which was explanted for decompression of a swollen brain or following severe head trauma and which was cryoconserved in the meantime is reimplanted. This procedure is the gold-standard therapy after decompressive hemicraniectomy and is routinely performed.
Study: NCT03982342

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cather closure of patent ductus arteriosus (PDA)
Description: Infants assigned to this group will have a catheter run from a blood vessel in the upper leg / groin area to the heart, where an FDA-approved device will be placed within the patent ductus arteriosus to occlude or plug it, thereby closing the ductus.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cather closure of patent ductus arteriosus (PDA)
Description: Infants assigned to this group will have a catheter run from a blood vessel in the upper leg / groin area to the heart, where an FDA-approved device will be placed within the patent ductus arteriosus to occlude or plug it, thereby closing the ductus.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative management of patent ductus arteriosus (PDA)
Description: Infants with a hemodynamically-significant patent ductus arteriosus randomized to this group will be treated by fluid restriction and possible diuretic use to reduce PDA symptoms, and allow time to permit the PDA to close or become reduced in size to the point where it is no longer considered hemodynamically-significant.
Study: NCT00526981

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prone position
Description: Prone position during spontaneous breathing.
Study: NCT03571763

Intervention type: OTHER
Intervention: SWI sequence
Description: Acute ischemic stroke patient confirmed by SWI sequence
Study: NCT03517384

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I-CBT for Body Dysmorphic Disorder
Description: The current intervention, is a therapist guided, Internet Cognitive Behavioral Therapy treatment for Body Dysmporhic Disorder which consists of 8 treatment modules administered over the course of 12 weeks.
Study: NCT00403754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: In the morning, powder filled capsules inhaled using a single dose dry powder inhaler (SDDPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: In the morning, powder filled capsules inhaled using a single dose dry powder inhaler (SDDPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: In the morning, powder filled capsules inhaled using a single dose dry powder inhaler (SDDPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: In the morning, powder filled capsules inhaled using a single dose dry powder inhaler (SDDPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to indacaterol was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to indacaterol was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to indacaterol was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to indacaterol was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Description: Salmeterol 100 μg total dose taken on Day 1. 50 μg in the morning and 50 μg twelve hours post initial dose inhaled via Diskus®, an inhalation device for Salmeterol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Description: Salmeterol 100 μg total dose taken on Day 1. 50 μg in the morning and 50 μg twelve hours post initial dose inhaled via Diskus®, an inhalation device for Salmeterol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Description: Salmeterol 100 μg total dose taken on Day 1. 50 μg in the morning and 50 μg twelve hours post initial dose inhaled via Diskus®, an inhalation device for Salmeterol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Description: Salmeterol 100 μg total dose taken on Day 1. 50 μg in the morning and 50 μg twelve hours post initial dose inhaled via Diskus®, an inhalation device for Salmeterol.
Study: NCT01669967

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine 5 mg/kg in 250 ml of normal saline infused over 45 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diphenhydramine
Description: Diphenhydramine 50 mg in 250 ml of normal saline infused over 45 minutes.
Study: NCT02803853

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Intervention components will occur at the policy level (working with tribal leaders makers to sustain intervention components; food retail outlet level (working with grocery stores and owners to stock, promote, and sell healthier foods and beverages); neighborhood level (working with worksites and schools to deliver nutrition intervention sessions to youth and adults in intervention neighborhoods); household level (providing a social media program that provides parents and caregivers tips for healthier eating).
Study: NCT02823249

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 1.56 g L-Tryptophan

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 1.56 g L-Leucine

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 50 g Xylitol

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 75 g Erythritol

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 75 g Glucose

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Tap water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Tap water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Tap water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Tap water

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Tap water

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Tap water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric Tube

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric Tube

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric Tube

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric Tube

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Nasogastric Tube

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Nasogastric Tube
Study: NCT02979925

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Transcutaneous Magnetic Stimulation
Description: Active transcutaneous magnetic stimulation (TMS) at the target site of nerve damage/injury.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcutaneous Magnetic Stimulation
Description: Sham TMS will consist of the same parameters as active, however, the subject will be shielded from the magnetic field of the coil.
Study: NCT02041754

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IQP-AK-102

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04160351

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theranova 400
Description: medium cut-off dialyser

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Elisio-19H
Description: high flux dialyser
Study: NCT04343248

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitazoxanide
Description: Nitazoxanide 600 mg administered orally twice daily for six weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered orally twice daily for six weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin Super B-Complex
Description: Vitamin Super B-Complex administered orally twice daily to maintain the blind

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin Super B-Complex
Description: Vitamin Super B-Complex administered orally twice daily to maintain the blind
Study: NCT02708095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT01320982

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: minocycline
Description: minocycline 100 mg/bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pramipexole
Description: pramipexole 0.125, 0.25, 0.5 and 0.75 mg/bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetylsalicylic acid
Description: acetylsalicylic acid 500mg/ bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo bid
Study: NCT03530072

Intervention type: DIAGNOSTIC_TEST
Intervention: Karius Test
Description: Next Generation Sequencing
Study: NCT02930824

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CYP2C19 genotyping
Description: All proton pump inhibitors are metabolized in part by the CYP2C19 enzyme, which is encoded by the highly polymorphic CYP2C19 gene. Based on variations within this gene the effectiveness of the drug may be reduced.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CYP2C19 genotyping
Description: All proton pump inhibitors are metabolized in part by the CYP2C19 enzyme, which is encoded by the highly polymorphic CYP2C19 gene. Based on variations within this gene the effectiveness of the drug may be reduced.
Study: NCT02556840

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: insulin therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: insulin therapy
Study: NCT02540629

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bundled EMS CPR approach including dispatcher-assisted CPR, 3-person team CPR, and feedback CPR monitoring device
Description: Gold standard EMS CPR refers to our bundled approach to providing high quality EMS CPR through one or more intervention(s) as applicable including 1) dispatcher-assisted CPR, 2) multi-tiered team CPR, and 3) feedback CPR.
Study: NCT02368834

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychoeducation
Description: The intervention included a presentation by a psychiatrist, with parent manual provided, and then two group sessions at the 2nd and 4th weeks to address further concerns of the parents
Study: NCT00354432

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: oral soy protein/isoflavones powder
Description: Soy protein powder (20gm) orally 160 mg of total isoflavones isocaloric supplement of casein protein

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: oral soy protein/isoflavones powder
Description: Soy protein powder (20gm) orally 160 mg of total isoflavones isocaloric supplement of casein protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: Patients receive oral venlafaxine 75mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Venlafaxine
Description: Patients receive oral venlafaxine 75mg.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Powder
Description: Placebo powder (20gm casein protein) orally 0 mg of total isoflavones

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo Powder
Description: Placebo powder (20gm casein protein) orally 0 mg of total isoflavones

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Pill
Description: Patients receive oral placebo pill.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Pill
Description: Patients receive oral placebo pill.
Study: NCT02435342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalazatide
Description: Subcutaneous injection twice per week for a total of 9 doses, followed by four weeks of follow-up.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalazatide
Description: Subcutaneous injection twice per week for a total of 9 doses, followed by four weeks of follow-up.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo, Subcutaneous injection twice per week for a total of 9 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo, Subcutaneous injection twice per week for a total of 9 doses
Study: NCT01889238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: 160 mg administered as four soft gelatin capsules orally once daily
Study: NCT04132960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8201a
Description: Anti-HER2-antibody drug conjugate (ADC)
Study: NCT03769766

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin
Description: Take medication one 500 mg pill of BCM-95 taken twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take medication one 500mg pill twice daily
Study: NCT03369223

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986249
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986249
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986249
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986249
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986249
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986249
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986249
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986249
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986249
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days
Study: NCT04521361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)
Description: Drug will be administered as aqueous solution intravenously at a dose of 55 kBq/kg body weight every 4 weeks for 6 cycles (cycle length = 4 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)
Description: Drug will be administered as aqueous solution intravenously at a dose of 55 kBq/kg body weight every 4 weeks for 6 cycles (cycle length = 4 weeks).
Study: NCT03875287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: DOSING REGIMEN(S):~Level -1 10mg daily days 1-4~Level 1 10mg daily days 1-5~Level 2 15mg daily days 1-5~Level 3 20mg daily days 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cedazuridine
Description: DOSING REGIMEN(S):~Level -1 100mg daily days 1-4~Level 1 100mg daily days 1-5~Level 2 100mg daily days 1-5~Level 3 100mg daily days 1-5
Study: NCT02905422

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: H.E.A.L.T.H. II Intervention
Description: 12 month study with 6 month intervention phase and 6 month follow up phase. Participants will receive bi-weekly educational information pertaining to weight loss during the intervention phase. Participants will use online website to monitor weight, access meal plans, access weight loss information, and access fitness plans.
Study: NCT02473042

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation
Description: Electrical stimulation to the wrist initiated at 1mHz, 1 pulse/second using two leads on a nerve stimulator. Stimulation continued throughout the breast surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zofran
Description: 4 mg by vein for 1 dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zofran
Description: 4 mg by vein for 1 dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 10 mg by vein for 1 dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 10 mg by vein for 1 dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenergan
Description: 6.25 mg by vein for 1 dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenergan
Description: 6.25 mg by vein for 1 dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pepcid
Description: 10 mg by vein for 1 dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pepcid
Description: 10 mg by vein for 1 dose.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Questionnaire completed about 15 minutes after participant wakes up after surgery, then every 30 minutes until they leave the clinic. It should take about 2 - 3 minutes to complete the questionnaire.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire
Description: Questionnaire completed about 15 minutes after participant wakes up after surgery, then every 30 minutes until they leave the clinic. It should take about 2 - 3 minutes to complete the questionnaire.
Study: NCT00785785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib (AMN107)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imatinib (STI571)
Study: NCT03498937

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: 10 active tDCS sessions (2 sessions/day for 5 days, 30 min each, 2 mA) applied to the dlPFC
Study: NCT03226704

Intervention type: PROCEDURE
Intervention: Leukapheresis
Description: Leukapheresis
Study: NCT04280276

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: TruGraf test
Description: To obtain longitudinal TruGraf testing in patients with stable creatinine, high and normal IPV in tacrolimus levels, between 3 and 18 months post-transplant at the University of Maryland post-transplant clinic.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: TruGraf test
Description: To obtain longitudinal TruGraf testing in patients with stable creatinine, high and normal IPV in tacrolimus levels, between 3 and 18 months post-transplant at the University of Maryland post-transplant clinic.